TABLE 2.

Immune checkpoint inhibitors in ovarian cancer.

Immunotherapy agents	Target	Phase	Disease status	N	Trial number	References
CTLA-4 inhibitors
Ipilimumab	CTLA-4	–	Ovarian cancer	2	–	Hodi et al., 2003
		–	Stage IV ovarian cancer	9	–	Hodi et al., 2008
		Phase 2	Recurrent platinum-sensitive ovarian carcinoma	40	NCT01611558	–
PD-1 inhibitors
Nivolumab	PD-1	Phase 2	Platinum-resistant ovarian cancer	20	UMIN000005714	Hamanishi et al., 2015
Pembrolizumab		Phase 1b	Advanced ovarian cancer	26	NCT02054806	Varga et al., 2019
PD-L1 inhibitors
BMS-936559	PD-L1	Phase 1	Ovarian cancer	200	NCT00729664	Brahmer et al., 2012
Avelumab		Phase 1b	Refractory or relapsed ovarian cancer	125	NCT01772004	Disis et al., 2019